| Schedule of Reconciliation of the Company's Net Loss |
The following table presents the significant segment expenses regularly provided to the CODM and a reconciliation to net loss (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses |
|
$ |
10,982 |
|
|
$ |
2,827 |
|
|
$ |
28,211 |
|
|
$ |
8,273 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Schizophrenia programs |
|
|
36,394 |
|
|
|
25 |
|
|
|
73,635 |
|
|
|
512 |
|
Bipolar depression programs |
|
|
2,753 |
|
|
|
57 |
|
|
|
8,425 |
|
|
|
57 |
|
Formulation and CMC |
|
|
2,995 |
|
|
|
1,044 |
|
|
|
8,300 |
|
|
|
2,717 |
|
Preclinical and other direct expenses |
|
|
4,029 |
|
|
|
6 |
|
|
|
6,017 |
|
|
|
123 |
|
Total direct research and development expenses |
|
|
46,171 |
|
|
|
1,132 |
|
|
|
96,377 |
|
|
|
3,409 |
|
Personnel-related |
|
|
4,720 |
|
|
|
837 |
|
|
|
12,054 |
|
|
|
3,154 |
|
Consulting and other |
|
|
625 |
|
|
|
450 |
|
|
|
1,876 |
|
|
|
1,698 |
|
Total indirect and unallocated research and development expenses |
|
|
5,345 |
|
|
|
1,287 |
|
|
|
13,930 |
|
|
|
4,852 |
|
Total research and development expenses |
|
|
51,516 |
|
|
|
2,419 |
|
|
|
110,307 |
|
|
|
8,261 |
|
Total operating loss |
|
|
(62,498 |
) |
|
|
(5,246 |
) |
|
|
(138,518 |
) |
|
|
(16,534 |
) |
Non-operating income |
|
|
3,432 |
|
|
|
1,690 |
|
|
|
8,795 |
|
|
|
2,801 |
|
Net loss |
|
$ |
(59,066 |
) |
|
$ |
(3,556 |
) |
|
$ |
(129,723 |
) |
|
$ |
(13,733 |
) |
|